Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system / Vijay Kumar, Anand Prakash Singh, Nicholas Wheeler, Cristi L. Galindo, Jong-Joo Kim
ABSTRACT Background D-penicillamine (D-pen) is a copper-chelating drug and has immune-modulatory properties. D-pen is used to treat rheumatoid arthritis, Wilson’s disease, and kidney stones (cystinuria). However, associated adverse events (AEs) of D-pen treatment are frequent and often serious. Therefore, a comprehensive assessment of the safety profile of D-pen is urgently needed. Research design and methods We identified and analyzed AEs associated with D-pen between April-1970 to July-2020 from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) databases and calculated the reported odds ratio (ROR) with 95% confidence intervals (CI) using the disproportionality analysis. Results A total of 9,150,234 AEs related to drugs were reported in the FAERS database, of which 542 were related to D-Pen. We report that D-pen was associated with dystonia (ROR: 20.52; 95%CI: 12.46–33.80), drug hypersensitivity (ROR: 5.42; 95%CI: 3.72–7.90), pancytopenia (ROR: 10.20; 95%CI: 5.61–18.56), joint swelling (ROR: 9.07; 95%CI: 5.51–14.94), renal-impairment (ROR: 6.68; 95%CI: 3.67–12.15), dysphagia (ROR: 5.05; 95%CI: 2.76–8.89), aggravation of condition (ROR: 4.16; 95%CI: 2.60–6.67), congestive cardiac failure (ROR: 4.04; 95%CI: 2.22–7.35), peripheral edema (ROR: 3.77; 95%CI: 2.17–6.55), tremor (ROR: 3.46; 95%CI: 2.00–6.01), pyrexia (ROR: 3.46; 95%CI: 2.00–6.01), and gait disturbance (ROR: 2.41; 95%CI: 1.29–4.52). Conclusions Patients taking D-pen require close monitoring of renal function, blood counts, immunity, liver, cardiac function, and neurological function. D-pen suppresses immune system which maximizes the risk of infection.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
---|---|
Enthalten in: |
Expert opinion on drug safety - 20(2021), 11, Seite 1443- |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kumar, Vijay [VerfasserIn] |
---|
Links: |
FID Access [lizenzpflichtig] |
---|
Umfang: |
1 Online-Ressource (8 p) |
---|
doi: |
10.1080/14740338.2021.1956460 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
KFL009141650 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | KFL009141650 | ||
003 | DE-627 | ||
005 | 20230621210139.0 | ||
007 | cr uuu---uuuuu | ||
008 | 220511s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/14740338.2021.1956460 |2 doi | |
035 | |a (DE-627)KFL009141650 | ||
035 | |a (KFL)prod_LgpH_10.1080/14740338.2021.1956460 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
084 | |a PHARM |q DE-84 |2 fid | ||
100 | 1 | |a Kumar, Vijay |e verfasserin |4 aut | |
245 | 1 | 0 | |a Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system |c Vijay Kumar, Anand Prakash Singh, Nicholas Wheeler, Cristi L. Galindo, Jong-Joo Kim |
264 | 1 | |c 2021 | |
300 | |a 1 Online-Ressource (8 p) | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a ABSTRACT Background D-penicillamine (D-pen) is a copper-chelating drug and has immune-modulatory properties. D-pen is used to treat rheumatoid arthritis, Wilson’s disease, and kidney stones (cystinuria). However, associated adverse events (AEs) of D-pen treatment are frequent and often serious. Therefore, a comprehensive assessment of the safety profile of D-pen is urgently needed. Research design and methods We identified and analyzed AEs associated with D-pen between April-1970 to July-2020 from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) databases and calculated the reported odds ratio (ROR) with 95% confidence intervals (CI) using the disproportionality analysis. Results A total of 9,150,234 AEs related to drugs were reported in the FAERS database, of which 542 were related to D-Pen. We report that D-pen was associated with dystonia (ROR: 20.52; 95%CI: 12.46–33.80), drug hypersensitivity (ROR: 5.42; 95%CI: 3.72–7.90), pancytopenia (ROR: 10.20; 95%CI: 5.61–18.56), joint swelling (ROR: 9.07; 95%CI: 5.51–14.94), renal-impairment (ROR: 6.68; 95%CI: 3.67–12.15), dysphagia (ROR: 5.05; 95%CI: 2.76–8.89), aggravation of condition (ROR: 4.16; 95%CI: 2.60–6.67), congestive cardiac failure (ROR: 4.04; 95%CI: 2.22–7.35), peripheral edema (ROR: 3.77; 95%CI: 2.17–6.55), tremor (ROR: 3.46; 95%CI: 2.00–6.01), pyrexia (ROR: 3.46; 95%CI: 2.00–6.01), and gait disturbance (ROR: 2.41; 95%CI: 1.29–4.52). Conclusions Patients taking D-pen require close monitoring of renal function, blood counts, immunity, liver, cardiac function, and neurological function. D-pen suppresses immune system which maximizes the risk of infection | ||
700 | 1 | |a Singh, Anand Prakash |e verfasserin |4 aut | |
700 | 1 | |a Wheeler, Nicholas |e verfasserin |4 aut | |
700 | 1 | |a Galindo, Cristi L. |e verfasserin |4 aut | |
700 | 1 | |a Kim, Jong-Joo |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug safety |d Abingdon, Oxon : Routledge, Taylor & Francis, 2002 |g 20(2021), 11, Seite 1443- |h Online-Ressource |w (DE-627)KFL000006084 |w (DE-600)2114527-1 |w (DE-576)302969721 |x 1744-764X |7 nnns |
773 | 1 | 8 | |g volume:20 |g year:2021 |g number:11 |g pages:1443- |
856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/14740338.2021.1956460 |m X:KFL |x Resolving-System |x Verlag |y FID Access |z lizenzpflichtig |
912 | |a ZDB-1-TFE | ||
912 | |a GBV_KFL | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
935 | |i IMPORT_0628_prod_LgpH_02 | ||
951 | |a AR | ||
952 | |d 20 |j 2021 |e 11 |h 1443- |